SML1814

3,6-DMAD hydrochloride

≥98% (HPLC)

• Sinônimo(s): N9-(3-(Dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine hydrochloride
• Fórmula empírica (Notação de Hill): C₂₂H₃₂N₅ · xHCl
• Número CAS: 2187367-10-6
• Peso molecular: 366.52 (free base basis)
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• Formulário: powder
• condição de armazenamento: desiccated
• cor: yellow to orange
• solubilidade: DMSO: 25 mg/mL, clear
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: CN(C)CCCNC1=C2C(C=C(N(C)C)C=C2)=NC3=C1C=CC(N(C)C)=C3
• InChI: 1S/C22H31N5/c1-25(2)13-7-12-23-22-18-10-8-16(26(3)4)14-20(18)24-21-15-17(27(5)6)9-11-19(21)22/h8-11,14-15H,7,12-13H2,1-6H3,(H,23,24)
• chave InChI: UIWOQSJSDYDIQJ-UHFFFAOYSA-N

Descrição

Ações bioquímicas/fisiológicas

3,6-DMAD is also called as N⁹-(3-(dimethylamino)propyl)-N³,N³,N⁶,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts.[1]

3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.).

3,6-DMAD is an acridine derivative.

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable